SynthesisArquivos de neuro-psiquiatria2026
The entorhinal cortex atrophy score for diagnostic distinction between phases of the Alzheimer's disease continuum.
Synthesis in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is the most common type of dementia, causing functional impairment in millions of individuals and accounting for a large amount of healthcare costs. The entorhinal cortex appears to be one of the first brain structures affected by AD in its early stages. The Entorhinal Cortex Atrophy (ERICA) score is a visual atrophy score used by neuroradiologists in clinical practice for the diagnosis of AD. Objective: To analyze the effectiveness of the ERICA score for distinguishing between patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD dementia. Methods: A systematic review of the literature was conducted on the Science Direct, PubMed, Virtual Health Library, and Cochrane databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Of 1,413 studies identified, 6 were ultimately included in the present review, comprising 844 participants: 2 retrospective cohort studies and 4 cross-sectional studies. The methodological quality of the studies was assessed using the Newcastle-Ottawa scale. The focus was on the diagnostic performance of the ERICA score in the continuum phases of AD. Results: The ERICA score had lower sensitivity than the medial temporal lobe atrophy (MTA) score but higher specificity, reinforcing its importance for diagnostic accuracy, especially in contexts of clinical uncertainty. The ERICA score showed reproducibility between examiners similar to or greater than that of the MTA score. There are a few heterogeneous studies in the current literature on the applicability of the ERICA score in clinical practice. Conclusion: Diagnostic accuracy of the ERICA score is satisfactory in differentiating SCD or MCI from AD dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.